How AJICAP™ Compares to Other Site-Specific Conjugation Technologies
AJICAP™ combines the precision and homogeneity of site-specific conjugation with a purely chemical approach that works with native antibodies. Unlike approaches that rely on antibody engineering, introduced tags, or enzymatic steps to create defined conjugation sites, AJICAP™ enables precise DAR control without modifying the underlying antibody.
The comparison below highlights how AJICAP™ achieves site-specific conjugation while reducing the additional modifications and processing requirements associated with other approaches.
CharacteristicAJICAP™
Antibody modification requiredNo — native IgG
Enzymes requiredNo — pure chemistry
DAR homogeneityHigh — defined site
IgG subtype compatibilityBroad — confirm range
GMP track recordYes — via partner CDMOs
Peer-reviewed publications`12+
Process SimplicitySimple
Total YieldHigh
FlexibilityBroad Applicability
Resource EfficiencyHigher
CharacteristicCysteine engineering
Antibody modification requiredYes — cysteine mutations
Enzymes requiredNo
DAR homogeneityHigh — engineered site
IgG subtype compatibilityBroad
GMP track recordYes — multiple CDMOs
Peer-reviewed publicationsMany
Process SimplicityComplex
Total YieldModerate-Low
FlexibilityEngineering-dependent
Resource EfficiencyLower
CharacteristicEnzymatic Modification
Antibody modification requiredYes — aldehyde tags
Enzymes requiredYes — formylglycine-generating enzyme
DAR homogeneityHigh — defined site
IgG subtype compatibilityIgG1 primary
GMP track recordYes — industry CDMOs
Peer-reviewed publicationsSeveral
Process SimplicityModerate
Total YieldModerate
FlexibilityChemistry Constraints
Resource EfficiencyModerate
CharacteristicUnnatural amino acids
Antibody modification requiredYes — amber codon suppression
Enzymes requiredYes — amber codon suppression
DAR homogeneityNo
IgG subtype compatibilityHigh — defined site
GMP track recordLimited
Peer-reviewed publicationsSeveral
Process Simplicity?
Total Yield?
Flexibility?
Resource Efficiency?